SslE Elicits Functional Antibodies That Impair Mucinase Activity and Colonization by Both Intestinal and Extraintestinal Strains

English version České info

Escherichia coli are the predominant facultative anaerobe of the human colonic flora. Although intestinal and extraintestinal pathogenic E. coli are phylogenetically and epidemiologically distinct, we recently proposed a number of protective antigens conserved in most E. coli pathotypes. In this study, we have elucidated the function of the most promising of these antigens, SslE, which is characterized by the presence of a M60-like domain representative of a new extracellular zinc-metalloprotease sub-family. In particular, in vitro analysis of the ability of an sslE knockout mutant strain to transverse an agar-based mucin matrix revealed that SslE is essential to E. coli mucinase activity. Evidence showing that SslE induces functional antibodies, preventing both in vitro mucin degradation but also in vivo gut, kidney and spleen colonization, further support the hypothesis that SslE may facilitate E. coli colonization by favoring the penetration of the sterile inner mucus layer leading to interaction with host cells. Finally, the ability of SslE to also induce protective immunity against sepsis, linked to its presence among different pathotypes, supports the use of such an antigen as a broadly protective E. coli vaccine candidate.

Vyšlo v časopise: SslE Elicits Functional Antibodies That Impair Mucinase Activity and Colonization by Both Intestinal and Extraintestinal Strains. PLoS Pathog 10(5): e32767. doi:10.1371/journal.ppat.1004124
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004124

Souhrn

Zdroje

1. KaperJB, NataroJP, MobleyHL (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2: 123–140.

2. HartlandEL, LeongJM (2013) Enteropathogenic and enterohemorrhagic E. coli: ecology, pathogenesis, and evolution. Front Cell Infect Microbiol 3: 15.

3. CroxenMA, LawRJ, ScholzR, KeeneyKM, WlodarskaM, et al. (2013) Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26: 822–880.

4. GibsonJS, CobboldRN, TrottDJ (2010) Characterization of multidrug-resistant Escherichia coli isolated from extraintestinal clinical infections in animals. J Med Microbiol 59: 592–598.

5. van der DonkC, van de BovenkampJ, BamelisH, DriessenC, FeldhoffKH, et al. (2013) Prevalence and spread of multidrug-resistant Escherichia coli including ST131 in different patient populations in the Euroregion Meuse-Rhine. Future Microbiol 8: 1027–1037.

6. van der DonkCF, ScholsJM, DriessenCJ, HagenouwRG, MeulendijksA, et al. (2013) Prevalence and spread of multidrug resistant Escherichia coli isolates among nursing home residents in the southern part of The Netherlands. J Am Med Dir Assoc 14: 199–203.

7. JohnsonJR, TchesnokovaV, JohnstonB, ClabotsC, RobertsPL, et al. (2013) Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 207: 919–928.

8. PapadimitriouM, VoulgariE, RanellouK, KoemtzidouE, LebessiE, et al. (2011) Emergence of VIM-1 metallo-beta-lactamase-producing Escherichia coli in a neonatal intensive care unit. Microb Drug Resist 17: 105–108.

9. PoirelL, LagruttaE, TaylorP, PhamJ, NordmannP (2010) Emergence of metallo-beta-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother 54: 4914–4916.

10. MorielDG, BertoldiI, SpagnuoloA, MarchiS, RosiniR, et al. (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107: 9072–9077.

11. MorielDG, RosiniR, SeibKL, SerinoL, PizzaM, et al. (2012) Escherichia coli: great diversity around a common core. MBio 3: 3 may/june 2012; doi:10.1128/mBio.00118-12

12. IguchiA, ThomsonNR, OguraY, SaundersD, OokaT, et al. (2009) Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol 191: 347–354.

13. YangJ, BaldiDL, TauschekM, StrugnellRA, Robins-BrowneRM (2007) Transcriptional regulation of the yghJ-pppA-yghG-gspCDEFGHIJKLM cluster, encoding the type II secretion pathway in enterotoxigenic Escherichia coli. J Bacteriol 189: 142–150.

14. BaldiDL, HigginsonEE, HockingDM, PraszkierJ, CavaliereR, et al. (2012) The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect Immun 80: 2042–2052.

15. HernandesRT, De la CruzMA, YamamotoD, GironJA, GomesTA (2013) Dissection of the role of pili and the type 2 and 3 secretion systems in adherence and biofilm formation of an atypical enteropathogenic Escherichia coli strain. Infect Immun 81: 3793–802.

16. KorotkovKV, SandkvistM, HolWG (2012) The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol 10: 336–351.

17. StrozenTG, LiG, HowardSP (2012) YghG (GspSbeta) is a novel pilot protein required for localization of the GspSbeta type II secretion system secretin of enterotoxigenic Escherichia coli. Infect Immun 80: 2608–2622.

18. DecanioMS, LandickR, HaftRJ (2013) The non-pathogenic Escherichia coli strain W secretes SslE via the virulence-associated type II secretion system beta. BMC Microbiol 13: 130.

19. NakjangS, NdehDA, WipatA, BolamDN, HirtRP (2012) A novel extracellular metallopeptidase domain shared by animal host-associated mutualistic and pathogenic microbes. PLoS One 7: e30287.

20. WangP, GranadosRR (1997) An intestinal mucin is the target substrate for a baculovirus enhancin. Proc Natl Acad Sci U S A 94: 6977–6982.

21. LiuZ, MiyashiroT, TsouA, HsiaoA, GoulianM, et al. (2008) Mucosal penetration primes Vibrio cholerae for host colonization by repressing quorum sensing. Proc Natl Acad Sci U S A 105: 9769–9774.

22. SilvaAJ, LeitchGJ, CamilliA, BenitezJA (2006) Contribution of hemagglutinin/protease and motility to the pathogenesis of El Tor biotype cholera. Infect Immun 74: 2072–2079.

23. SheikhJ, CzeczulinJR, HarringtonS, HicksS, HendersonIR, et al. (2002) A novel dispersin protein in enteroaggregative Escherichia coli. J Clin Invest 110: 1329–1337.

24. HsiaoA, LiuZ, JoelssonA, ZhuJ (2006) Vibrio cholerae virulence regulator-coordinated evasion of host immunity. Proc Natl Acad Sci U S A 103: 14542–14547.

25. ColinaAR, AumontF, DeslauriersN, BelhumeurP, de RepentignyL (1996) Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase. Infect Immun 64: 4514–4519.

26. ZhouJS, GopalPK, GillHS (2001) Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro. Int J Food Microbiol 63: 81–90.

27. LaneMC, AlteriCJ, SmithSN, MobleyHL (2007) Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A 104: 16669–16674.

28. RheeKJ, ChengH, HarrisA, MorinC, KaperJB, et al. (2011) Determination of spatial and temporal colonization of enteropathogenic E. coli and enterohemorrhagic E. coli in mice using bioluminescent in vivo imaging. Gut Microbes 2: 34–41.

29. TorresAG, CiezaRJ, Rojas-LopezM, BlumentrittCA, SouzaCS, et al. (2012) In vivo bioluminescence imaging of Escherichia coli O104:H4 and role of aerobactin during colonization of a mouse model of infection. BMC Microbiol 12: 112.

30. SmithSN, HaganEC, LaneMC, MobleyHL (2010) Dissemination and systemic colonization of uropathogenic Escherichia coli in a murine model of bacteremia. MBio 1(5): e00262–10 doi:10.1128/mBio.00262-10

31. NicklassonM, SjolingA, von MentzerA, QadriF, SvennerholmAM (2012) Expression of colonization factor CS5 of enterotoxigenic Escherichia coli (ETEC) is enhanced in vivo and by the bile component Na glycocholate hydrate. PLoS One 7: e35827.

32. BienJ, SokolovaO, BozkoP (2012) Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage. Int J Nephrol 2012: 681473.

33. VigilPD, StapletonAE, JohnsonJR, HootonTM, HodgesAP, et al. (2011) Presence of putative repeat-in-toxin gene tosA in Escherichia coli predicts successful colonization of the urinary tract. MBio 2: e00066-00011.

34. PastorelloI, Rossi PaccaniS, RosiniR, MatteraR, Ferrer NavarroM, et al. (2013) EsiB, a Novel Pathogenic Escherichia coli Secretory Immunoglobulin A-Binding Protein Impairing Neutrophil Activation. MBio 4: 4 july/august 2013; doi:10.1128/mBio.00206-13

35. NestaB, SpraggonG, AlteriC, MorielDG, RosiniR, et al. (2012) FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3: 2 march/april 2012; doi:10.1128/mBio.00010-12

36. SchluterJ, FosterKR (2012) The evolution of mutualism in gut microbiota via host epithelial selection. PLoS Biol 10: e1001424.

37. HooperLV, MacphersonAJ (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10: 159–169.

38. RolN, FavreL, BenyacoubJ, CorthesyB (2012) The role of secretory immunoglobulin A in the natural sensing of commensal bacteria by mouse Peyer's patch dendritic cells. J Biol Chem 287: 40074–40082.

39. JongeneelCV, BouvierJ, BairochA (1989) A unique signature identifies a family of zinc-dependent metallopeptidases. FEBS Lett 242: 211–214.

40. LenartA, DudkiewiczM, GrynbergM, PawlowskiK (2013) CLCAs - a family of metalloproteases of intriguing phylogenetic distribution and with cases of substituted catalytic sites. PLoS One 8: e62272.

41. CarringtonSD, IrwinJA, LiuL, RuddPM, MatthewsE, et al. (2012) Analysing mucin degradation. Methods Mol Biol 842: 191–215.

42. ShengYH, HasnainSZ, PngCW, McGuckinMA, LindenSK (2012) Techniques for assessment of interactions of mucins with microbes and parasites in vitro and in vivo. Methods Mol Biol 842: 297–312.

43. BrumbaughAR, MobleyHL (2012) Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11: 663–676.

44. WieserA, RomannE, MagistroG, HoffmannC, NorenbergD, et al. (2010) A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 78: 3432–3442.

45. SvennerholmAM, TobiasJ (2008) Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 7: 795–804.

46. ZhangW, SackDA (2012) Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines 11: 677–694.

47. AhmedT, BhuiyanTR, ZamanK, SinclairD, QadriF (2013) Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev 7: CD009029.

48. LindenSK, SuttonP, KarlssonNG, KorolikV, McGuckinMA (2008) Mucins in the mucosal barrier to infection. Mucosal Immunol 1: 183–197.

49. GristM, ChakrabortyJ (1994) Identification of a mucin layer in the urinary bladder. Urology 44: 26–33.

50. AchtmanM, MercerA, KusecekB, PohlA, HeuzenroederM, et al. (1983) Six widespread bacterial clones among Escherichia coli K1 isolates. Infect Immun 39: 315–335.

51. KlockHE, LesleySA (2009) The Polymerase Incomplete Primer Extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol Biol 498: 91–103.

52. TamuraK, DudleyJ, NeiM, KumarS (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596–1599.

53. HagbergL, EngbergI, FreterR, LamJ, OllingS, et al. (1983) Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect Immun 40: 273–283.